IL-23 inhibitors in ulcerative colitis — the selective biologics targeting the p19 subunit of interleukin-23 (mirikizumab, risankizumab, guselkumab) demonstrating superior efficacy and safety profiles in head-to-head trials representing the fastest-growing drug class — create the most clinically differentiated market opportunity, with the Ulcerative Colitis Market reflecting IL-23 inhibitors as the next-generation commercial driver.

Mirikizumab (Omvoh) clinical differentiation — the Eli Lilly IL-23p19 inhibitor achieving approximately fifty percent clinical remission at one year and demonstrating superiority over ustekinumab in the VIVID-1 trial creating the competitive positioning. Mirikizumab receiving FDA approval in 2023 with both IV induction and SC maintenance dosing, with corticosteroid-free remission rates of approximately forty-five percent representing a significant advance over anti-TNF benchmarks.

Risankizumab (Skyrizi) expansion — the AbbVie IL-23 inhibitor already dominant in psoriasis and Crohn's disease gaining ulcerative colitis approval in 2024 with INSPIRE and COMMAND trials showing approximately sixty percent clinical response creating the cross-indication platform leverage. Risankizumab's established manufacturing, reimbursement, and physician familiarity accelerating UC adoption, with approximately twenty-five percent of biologic-naive patients achieving remission.

Guselkumab (Tremfya) dual mechanism — the Janssen IL-23p19 inhibitor with additional IL-12 neutralization (like ustekinumab) showing approximately fifty-five percent clinical response in the QUASAR trial creating the mechanism differentiation. Guselkumab receiving FDA approval in 2024 with subcutaneous induction option in 2025, offering convenience advantage over IV-only competitors.

Do you think IL-23 inhibitors will replace anti-TNF agents as first-line biologic therapy for moderate-to-severe UC, or will cost, prior authorization requirements, and anti-TNF biosimilar pricing maintain infliximab and adalimumab as initial choices?

What are the approved IL-23 inhibitors for ulcerative colitis and their key clinical data? Mirikizumab (Omvoh — Eli Lilly): IV induction 300mg (weeks 0, 4, 8); SC maintenance 200mg q8wk; VIVID-1: 50% clinical remission at 1 year; 45% corticosteroid-free remission; superior to ustekinumab; FDA approved 2023; Risankizumab (Skyrizi — AbbVie): IV induction 600mg (weeks 0, 4); SC maintenance 360mg q8wk; INSPIRE/COMMAND: 60% clinical response; 25% biologic-naive remission; FDA approved 2024; Guselkumab (Tremfya — Janssen): SC induction 200mg (weeks 0, 4); SC maintenance 100mg q8wk; QUASAR: 55% clinical response; FDA approved 2024; SC induction 2025; mechanism: all target IL-23p19 (vs. ustekinumab IL-12/23); safety: lower infection rates than anti-TNF; no black box warnings; cost: $15,000-25,000/year (similar to anti-TNF originators).

How do IL-23 inhibitors compare to existing biologic therapies in ulcerative colitis? Efficacy: IL-23 — 45-50% remission (biologic-experienced); anti-TNF — 20-30% remission (after failure); ustekinumab — 35-40% remission; vedolizumab — 35-40% remission; safety: IL-23 — lowest infection risk; no TB reactivation; no demyelination signal; anti-TNF — highest infection, TB, malignancy risk; vedolizumab — gut-selective, lowest systemic risk; positioning: IL-23 — emerging first-line for moderate-severe; anti-TNF — biosimilar cost advantage ($5,000-10,000/year); vedolizumab — gut-selective preference; ustekinumab — established, broader IBD experience; market impact: IL-23 class — $2-3B UC sales potential by 2030.

#UlcerativeColitis #IL23Inhibitors #IBDTreatment #Mirikizumab #Skyrizi #Tremfya